AI-generated analysis. Always verify with the original filing.
This 20-F/A amendment for Telix Pharmaceuticals Limited for fiscal year 2025, filed on March 20, 2026, is a technical correction to the original filing. The amendment specifically corrects hyperlinks for Exhibits 4.17, 4.18, 8.1, 11.1, 12.1, 12.2, 13.1, and 13.2, and includes new officer certifications (Exhibits 12.3 and 12.4). The filing explicitly states that no financial statements are included in this amendment, no financial information has been amended or updated, and no changes have been made to the financial statements from the original filing. The company confirms it is a large accelerated filer, uses International Financial Reporting Standards (IFRS) for its financial statements, and had 338,777,049 ordinary shares outstanding as of December 31, 2025. The report should be read together with the original annual report for complete financial information.